{"text": "a car t from bristol myers benefits myeloma patients at earlier stage of care bmy tsvt jnj legn"}
{"text": "bmy tsvt abecma idecabtagene vicleucel reduced the risk of disease progression or death by 51 versus standard regimens in earlier lines of therapy for relapsed and refractory multiple myeloma base"}
{"text": "abecma cuts risk of progression death by 51 in earlier line myeloma bmy tsvt"}
{"text": "jnj bmy legn bristol myers 2seventy post late stage data for car t therapy in multiple myeloma"}
{"text": "bmy bristol myers and 2seventy bio tsvt confirm the first publication and presentation of positive results"}
{"text": "gsk wins full approval for cancer immunotherapy looks to expand use gsk mrk bmy"}
